-
2023-505239-10-00
6
2024-03-19
Primary (essential) hypertension
-
2023-506792-94-00
11
2024-03-04
Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
-
2023-503220-76-01
6
2024-02-13
Unexplained recurrent miscarriages
-
2023-503521-19-00
5
2024-02-09
Duchenne muscular dystrophy (DMD)
-
2024-511537-35-00
9
2024-02-09
Metastatic castration-resistant prostate cancer (mCRPC)
-
2023-504146-60-00
10
2024-02-07
lymphatic malformations associated with PIK3CA mutation
-
2023-506698-36-00
5
2024-02-02
low-volume metastatic castration-sensitive prostate cancer
-
2023-505379-61-00
4
2024-01-17
Acute Myeloid Leukaemia
-
2023-507466-40-00
6
2024-01-12
Prostate cancer
-
2022-502685-25-00
10
2024-01-01
The trial population will consist of patients with LAVC who require pr
-
2023-504637-42-01
6
2023-12-21
aortic valve stenosis
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2023-510541-25-00
1
2023-10-09
Relapsed/Refractory B-cell Malignancies
-
2023-507171-22-00
9
2023-06-21
Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
-
2022-501620-26-00
6
2023-05-15
prosthetic joint infection
-
2023-504897-39-00
1
2023-04-13
Advanced or refractory solid tumours (Part 1)
-
2024-510766-16-00
11
2023-03-06
Pancreatoduodenectomy with a high risk for contaminated bile
-
2023-507233-19-00
10
2023-02-16
Treatment of IgAN
-
2022-502140-13-00
6
2023-01-11
Atrial fibrillation
Acute coronary syndrome
Chronic coronary syndrome
-
2024-514328-18-00
7
2022-12-06
Spinocerebellar ataxia types 1, 3 and Huntington's disease
-
2023-507041-28-00
4
2022-11-28
Solid and Hematological Malignancies
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2023-509462-38-00
11
2022-10-25
Patients with advanced cancer.
-
2024-511979-15-00
4
2022-10-14
relapsed/refractory Non-Hodgkin Lymphoma